In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s ...

2024 was a pivotal year for the patient support landscape, as the space underwent a substantial shift shaped by market dynamics, regulatory changes, and the evolving needs of patients. After a quarter ...

In recent years, the landscape of retail pharmacy has changed significantly due to massive financial, legislative, and social pressures, creating a challenging environment for both large and small ...

The pharmaceutical industry has witnessed a resurgence of mergers and acquisitions (M&As) as companies seek to gain a competitive edge, accelerate innovation, and drive growth. By consolidating ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, describes what the approach of pharma ...

Illicit trade activity (ITA) in the pharmaceutical industry has been on a steady rise globally since the Pharmaceutical Security Institute (PSI) began reporting annual incident statistics more than 22 ...

However, the 10% tariff on imports from China went into effect this morning, with the nation imposing several of it own. The pause will allow time for negotiations on the immigration (via increased ...

Merck’s recent earnings call revealed that although the company generated worldwide sales of $64.2 billion—an 7% increase over 2023—the company will be temporarily suspending Gardasil shipments to ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, describes the highlights of a recent pharma ...

New engagement approaches can help drive treatment gains in underrepresented communities. There is no doubt that diversity of those who participate in clinical trials is of utmost importance, but, ...

A bipartisan government funding deal at the end of last year initially included reforms of pharmacy benefit managers (PBMs) that would limit their ability to use rebates as a major profit center. PBM ...